- Home
- VIR vs QBTS Comparison
VIR vs QBTS Comparison
Compare VIR & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- QBTS
- Stock Information
- Founded
- VIR 2016
- QBTS 1999
- Country
- VIR United States
- QBTS United States
- Employees
- VIR N/A
- QBTS N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- QBTS Retail: Computer Software & Peripheral Equipment
- Sector
- VIR Health Care
- QBTS Technology
- Exchange
- VIR Nasdaq
- QBTS Nasdaq
- Market Cap
- VIR 844.9M
- QBTS N/A
- IPO Year
- VIR 2019
- QBTS N/A
- Fundamental
- Price
- VIR $5.41
- QBTS $10.42
- Analyst Decision
- VIR Strong Buy
- QBTS Strong Buy
- Analyst Count
- VIR 7
- QBTS 6
- Target Price
- VIR $33.57
- QBTS $8.42
- AVG Volume (30 Days)
- VIR 1.0M
- QBTS 35.2M
- Earning Date
- VIR 05-07-2025
- QBTS 05-08-2025
- Dividend Yield
- VIR N/A
- QBTS N/A
- EPS Growth
- VIR N/A
- QBTS N/A
- EPS
- VIR N/A
- QBTS N/A
- Revenue
- VIR $20,861,000.00
- QBTS $21,363,000.00
- Revenue This Year
- VIR N/A
- QBTS $157.15
- Revenue Next Year
- VIR $10.65
- QBTS $54.79
- P/E Ratio
- VIR N/A
- QBTS N/A
- Revenue Growth
- VIR N/A
- QBTS 121.61
- 52 Week Low
- VIR $4.95
- QBTS $0.75
- 52 Week High
- VIR $14.45
- QBTS $11.95
- Technical
- Relative Strength Index (RSI)
- VIR 35.98
- QBTS 70.46
- Support Level
- VIR $5.83
- QBTS $6.82
- Resistance Level
- VIR $6.29
- QBTS $7.95
- Average True Range (ATR)
- VIR 0.31
- QBTS 0.70
- MACD
- VIR 0.02
- QBTS 0.23
- Stochastic Oscillator
- VIR 28.80
- QBTS 90.45
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.